ContraFect focuses on discovering and developing therapeutic proteins and monoclonal antibodies, with lysin programs aimed at treating drug‑resistant bacterial infections. Its initial product candidates target antibiotic‑resistant pathogens such as MRSA and influenza, and the company is researching lysins to target Gram‑negative bacteria including Pseudomonas aeruginosa. ContraFect emphasizes targeting conserved regions of bacteria or viruses that are less prone to mutation. The company announced eligibility for up to $2.1 million in funding from CARB‑X to advance its Gram‑negative lysin program. The award is structured as $1.1 million in initial funding with up to an additional $1.0 million contingent on achievement of milestones over the next two years. The press release also includes forward‑looking statements noting risks and uncertainties related to development and future results. ContraFect develops monoclonal antibodies and lysins aimed at treating life‑threatening bacterial and viral infections. Its lysin programs target drug‑resistant gram‑positive bacteria, including MRSA, streptococcus, and intestinal infections. The company is pursuing a shift from conventional monotherapy to combinatorial multi‑therapy using antibody and lysin combinations. Recent financings will be used to fund research and development and to advance the company's first products into clinical development. The company closed a $2.2M Series A and a $12M Series B to support these plans. Headquartered in New York, NY, ContraFect is focused on addressing growing drug resistance and therapy escape mechanisms used by pathogens.

Total raised

$16M

Funding rounds

3

Latest round

Series A

Latest activity

Oct 2010